ATE376187T1 - Nachweis von erkrankungen der nieren und behandlung - Google Patents

Nachweis von erkrankungen der nieren und behandlung

Info

Publication number
ATE376187T1
ATE376187T1 AT99959616T AT99959616T ATE376187T1 AT E376187 T1 ATE376187 T1 AT E376187T1 AT 99959616 T AT99959616 T AT 99959616T AT 99959616 T AT99959616 T AT 99959616T AT E376187 T1 ATE376187 T1 AT E376187T1
Authority
AT
Austria
Prior art keywords
disease
kidneys
diseases
detection
treatment
Prior art date
Application number
AT99959616T
Other languages
English (en)
Inventor
Wayne Comper
Original Assignee
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP7843A external-priority patent/AUPP784398A0/en
Application filed by Univ Monash filed Critical Univ Monash
Application granted granted Critical
Publication of ATE376187T1 publication Critical patent/ATE376187T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
AT99959616T 1998-12-21 1999-12-20 Nachweis von erkrankungen der nieren und behandlung ATE376187T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP7843A AUPP784398A0 (en) 1998-12-21 1998-12-21 Kidney disease detection and treatment
US09/415,217 US6447989B1 (en) 1998-12-21 1999-10-12 Kidney disease detection and treatment

Publications (1)

Publication Number Publication Date
ATE376187T1 true ATE376187T1 (de) 2007-11-15

Family

ID=25645955

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99959616T ATE376187T1 (de) 1998-12-21 1999-12-20 Nachweis von erkrankungen der nieren und behandlung

Country Status (13)

Country Link
US (3) US6589748B2 (de)
EP (1) EP1141728B1 (de)
JP (2) JP4160263B2 (de)
CN (1) CN1331801A (de)
AT (1) ATE376187T1 (de)
AU (1) AU1674400A (de)
BR (1) BR9916407A (de)
CA (1) CA2356174A1 (de)
DE (1) DE69937368T2 (de)
DK (1) DK1141728T3 (de)
IL (1) IL143892A0 (de)
MX (1) MXPA01006404A (de)
WO (1) WO2000037944A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP784398A0 (en) 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
BR9916407A (pt) 1998-12-21 2001-09-25 Univ Monash Detecção e tratamento de doenças dos rins
US7250294B2 (en) * 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
DK1384075T3 (da) 2001-03-28 2010-04-26 Heska Corp Fremgangsmåder til detektering af tidlig renal sygdom hos dyr
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
WO2004073864A2 (en) * 2003-02-13 2004-09-02 Becton, Dickinson And Company Devices for component removal during blood collection, and uses thereof
WO2004084841A2 (en) 2003-03-27 2004-10-07 Heska Corporation Novel anti-feline albumin antibodies and methods of detecting early renal disease
CA2535156A1 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
DK1817058T3 (en) * 2004-11-24 2015-12-07 Hills Pet Nutrition Inc COMPOSITION FOR USE FOR IMPROVING THE hepatic clearance xenobiotics WITH AN ANIMAL
US8647660B2 (en) 2004-12-29 2014-02-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
JP5295567B2 (ja) * 2004-12-30 2013-09-18 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 高齢期の動物の生活の質を高めるための方法
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
CN101198259B (zh) * 2005-04-19 2014-05-28 希尔氏宠物营养品公司 用于预防和治疗肾脏疾病的方法和组合物
US20080293621A1 (en) * 2005-04-29 2008-11-27 Timothy Arthur Allen Methods for Prolonging Feline Life
BRPI0610060A2 (pt) * 2005-05-20 2010-05-25 Hills Pet Nutrition Inc método para promover a saúde ou bem estar em um animal adulto, método para regular a ingestão de rações por um animal adulto, kit, meios para comunicar informação sobre ou instruções para promover a saúde ou bem estar em um animal adulto, método para aumentar a retenção de nitrogênio por um animal adulto, processo para fabricar uma ração, produto, e, ração
CA2613788C (en) * 2005-06-29 2016-08-23 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
RU2377980C2 (ru) * 2005-08-17 2010-01-10 Хилл`С Пет Ньютришн, Инк. Способы и композиции для профилактики и лечения заболеваний почек
EP2118666B1 (de) * 2007-03-07 2011-08-03 Mosaiques Diagnostics And Therapeutics AG Verfahren zur normierung der konzentration von analyten in einer urinprobe
EP1972940A1 (de) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Nierenerkrankungen
US9000134B2 (en) * 2007-05-11 2015-04-07 Wallace B. Haigh Reagent and kit for early diagnosis of kidney disease
EP2198305A2 (de) * 2007-10-09 2010-06-23 Mosaiques Diagnostics And Therapeutics AG Polypeptidmarker zur diagnose von prostatakrebs
EP2051078A1 (de) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Diabetes Mellitus
EP2255203A2 (de) * 2008-03-19 2010-12-01 Mosaiques Diagnostics And Therapeutics AG Verfahren und marker zur diagnose von tubulären nierenschäden und -erkrankungen
CA2731065C (en) 2008-07-18 2018-09-18 Boston Medical Center Corporation Diagnostics for membranous nephropathy
BRPI0917711A2 (pt) * 2008-08-28 2017-06-20 Astute Medical Inc método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
EP2324354B1 (de) * 2008-08-29 2014-07-16 Astute Medical, Inc. Verfahren zur prognose von akuter niereninsuffizienz
EP2338054A1 (de) * 2008-09-17 2011-06-29 Mosaiques Diagnostics And Therapeutics AG Nierenzellkarzinom
CN104391115B (zh) * 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
NZ619918A (en) * 2008-10-21 2015-04-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BRPI0922021A2 (pt) 2008-11-10 2019-09-24 Astute Medical Inc método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
CN104034901A (zh) * 2008-11-22 2014-09-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US8481324B2 (en) 2008-12-04 2013-07-09 Technion Research And Development Foundation Ltd. Apparatus and methods for diagnosing renal disorders
DK2391653T3 (en) * 2009-01-28 2015-02-09 Ind Tech Res Inst Biomarkers associated nephropathy
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5827226B2 (ja) * 2009-08-07 2015-12-02 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
EP3151005A1 (de) * 2009-08-28 2017-04-05 Astute Medical, Inc. Verfahren zur diagnose von nierenläsion und niereninsuffizienz
CA2779905A1 (en) * 2009-11-07 2011-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX340078B (es) 2009-11-07 2016-06-24 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
KR20120123056A (ko) 2009-12-20 2012-11-07 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
EP2531620B1 (de) 2010-02-05 2016-12-14 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
AU2011269847A1 (en) 2010-02-26 2013-01-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2539712A4 (de) 2010-02-26 2013-09-18 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2585827A4 (de) 2010-06-23 2013-12-04 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
US8930222B2 (en) * 2010-08-05 2015-01-06 Abbott Laboratories Method and system for managing patient healthcare
DE102010038014B4 (de) 2010-10-06 2021-10-07 Numares Ag Verwendung spezifischer Substanzen als Marker zur Bestimmung des Risikos einer Nierenabstoßung
KR101215759B1 (ko) 2010-11-01 2012-12-26 서울대학교산학협력단 오로소뮤코이드를 포함하는 조성물의 용도
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
CN102854325B (zh) * 2011-07-01 2015-01-07 复旦大学 胰岛素与血清蛋白可逆性结合的亲和力指标测定方法及应用
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US20130115640A1 (en) * 2011-11-03 2013-05-09 James A. Tumlin ACTH for Treatment of Kidney Disease
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9689826B2 (en) 2012-03-11 2017-06-27 Technion Research And Development Foundation Ltd. Detection of chronic kidney disease and disease progression
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
ES2681955T3 (es) 2013-01-17 2018-09-17 Astute Medical, Inc. Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
JP2016188761A (ja) * 2013-08-23 2016-11-04 国立研究開発法人国立国際医療研究センター 糖尿病腎症の発症または発症リスクの検出方法及びキット
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
CN104007258B (zh) * 2013-09-30 2016-07-06 中国医学科学院基础医学研究所 局灶性节段性肾小球硬化的蛋白标志物
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
CN104849466A (zh) * 2014-02-14 2015-08-19 张曼 尿液玻璃体结合蛋白在2型糖尿病合并早期肾损伤诊治中的应用
WO2016012864A2 (en) * 2014-07-23 2016-01-28 University Of British Columbia Biomarkers for anderson-fabry disease
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
EP3665705B1 (de) 2017-08-08 2024-12-18 Fresenius Medical Care Holdings, Inc. Systeme und verfahren zur behandlung und schätzung des fortschreitens einer chronischen nierenerkrankung
CN107561175A (zh) * 2017-08-10 2018-01-09 武汉大学 一种肾小球硬化大鼠模型的评价方法
RU2697722C1 (ru) * 2018-12-06 2019-08-19 Ирина Сергеевна Шатохина Способ диагностики активности воспалительного процесса при латентном течении хронического пиелонефрита
CN110632229A (zh) * 2019-09-24 2019-12-31 华兰生物工程重庆有限公司 高效液相色谱仪检测静注人免疫球蛋白(pH4)蛋白质含量的方法
CN111714517A (zh) * 2020-04-14 2020-09-29 南开大学 一种溶酶体作为制备药物领域的应用
RU2768464C1 (ru) * 2021-04-27 2022-03-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ диагностики мембранозной нефропатии как одной из форм хронического гломерулонефрита

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994165A (en) * 1989-02-16 1991-02-19 Cornell Research Foundation, Inc. Liquid junction coupling for capillary zone electrophoresis/ion spray spectrometry
CA2080250A1 (en) 1991-05-24 1992-11-25 Hirokazu Suzuki Method of diagnosing renal diseases
JPH0682446A (ja) * 1992-08-31 1994-03-22 Wakamoto Pharmaceut Co Ltd 腎疾患の診断法
DE4336498A1 (de) * 1993-10-26 1995-04-27 Bender & Co Gmbh Verfahren zur Diagnose von Nieren- und Gefäßerkrankungen
US5534431A (en) * 1994-02-28 1996-07-09 The Board Of Regents Of The University Of Nebraska Hybridomas and monoclonal antibodies specific for unique determinants of nephropathy-related immunoglobulin G and complexes thereof
US5908925A (en) 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US5800998A (en) * 1996-11-12 1998-09-01 Millennium Pharmaceuticals, Inc. Assays for diagnosing type II diabetes in a subject
BR9916407A (pt) 1998-12-21 2001-09-25 Univ Monash Detecção e tratamento de doenças dos rins

Also Published As

Publication number Publication date
US20020022236A1 (en) 2002-02-21
MXPA01006404A (es) 2003-06-06
EP1141728A4 (de) 2005-01-12
JP4388515B2 (ja) 2009-12-24
US6589748B2 (en) 2003-07-08
EP1141728B1 (de) 2007-10-17
US20020012906A1 (en) 2002-01-31
US20040106155A1 (en) 2004-06-03
DK1141728T3 (da) 2008-02-04
AU1674400A (en) 2000-07-12
JP2002533680A (ja) 2002-10-08
WO2000037944A1 (en) 2000-06-29
DE69937368D1 (de) 2007-11-29
IL143892A0 (en) 2002-04-21
JP4160263B2 (ja) 2008-10-01
JP2006038877A (ja) 2006-02-09
CN1331801A (zh) 2002-01-16
EP1141728A1 (de) 2001-10-10
DE69937368T2 (de) 2008-07-17
BR9916407A (pt) 2001-09-25
CA2356174A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
ATE376187T1 (de) Nachweis von erkrankungen der nieren und behandlung
DE69530861D1 (de) Vorrichtung zur durchführung eines oder mehrerer kompetitiver immunoassays
DE69522831D1 (de) Assays und vorrichtungen zum nachweis von extrahepatischer biliäreratresie
ATE15229T1 (de) Verfahren zum nachweisen von okkultem humanblut in humanstuhlproben.
DK0770876T3 (da) En screening-fremgangsmåde til at identificere ligander for målproteiner
ATE267399T1 (de) Verfahren zum nachweis von komplex-gebundenem prostata-spezifischem antigen (kpsa)
EP0165681A3 (de) Verfahren zum Nachweis von drogeninduzierter Thrombozytopenia und in diesem Verfahren zu verwendender Immunosatz
CY1107621T1 (el) Μεθοδος ανιχνευσης αντισωματων σε ενα δειγμα
EA199800493A1 (ru) Анализ крови на соотношение активности фактора v для оценки вероятности заболевания тромбоэмболией
NO953770L (no) Analysemetode
ATE397215T1 (de) Entstörung von immunoassays durch substanzen, die aus den framework-regionen von antikörpern abgeleitet sind
EA199900775A1 (ru) Быстрый способ диагностики рака
ATE105086T1 (de) Diagnostisches mittel und verfahren zur bestimmung von apolipoprotein b.
FI910324A7 (fi) Menetelmät ja testipakkaukset ihmisen leukosyyttiantigeeni-DNA:n havaitsemiseksi
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
NO973823L (no) Påvisning av antistoffproduksjon
EP1281083A4 (de) Verfahren zur erkennung von entzündungen und entzündungsbedingungen
ATE192236T1 (de) Menschliche phospholipase aktivierender proteinteil
ATE208040T1 (de) Immunoassay-reagenzien, testsätze und verfahren
DE60033190D1 (de) Verfahren zum nachweis von hepatitis c antigenen
ATE367582T1 (de) Verfahren zum nachweis von borna-disease-virus (bdv)- infektionen
IL143639A0 (en) Method for determining the activity of a substance using a functional test in vitro
ATE232299T1 (de) Immunoassay zur bestimmung von psa-act
DE69809576D1 (de) Immuntest zum nachweis von menschlichen cytomegalovirus spezifischen igm
DE69533200D1 (de) Verfahren zur prüfung von immunokompetenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1141728

Country of ref document: EP

REN Ceased due to non-payment of the annual fee